COMMUNIQUÉS West-GlobeNewswire

Orion Corporation: Managers’ transactions – Eija Ronkainen

06/05/2024 - 11:00

ORION CORPORATION MANAGERS’ TRANSACTIONS 6 MAY 2024 at 12.00 EEST Orion Corporation: Managers’ transactions – Eija Ronkainen Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No [...]

Orion Corporation: Managers’ transactions – Ari Lehtoranta

06/05/2024 - 11:00

ORION CORPORATION MANAGERS’ TRANSACTIONS 6 MAY 2024 at 12.00 EEST Orion Corporation: Managers’ transactions – Ari Lehtoranta Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No [...]

Orion Corporation: Managers’ transactions – Kari Jussi Aho

06/05/2024 - 11:00

ORION CORPORATION MANAGERS’ TRANSACTIONS 6 MAY 2024 at 12.00 EEST Orion Corporation: Managers’ transactions – Kari Jussi Aho Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No [...]

Virbac : Declaration of the number of shares and voting rights

06/05/2024 - 10:28

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]

Virbac : Déclaration d'actions et de droits de vote 04/2024

06/05/2024 - 10:28

DECLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]

Curium Announces First Commercial Doses in Germany of PYLCLARI® – An Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer

06/05/2024 - 10:25

PARIS, May 06, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced that today in Munich and Nurnberg, Germany the first commercial doses of PYLCLARI ® have been delivered. PYLCLARI ® (INN: [...]

Health Canada Approves Nexstim NBS 6 System for Treatment of MDD

06/05/2024 - 08:00

Press release, Helsinki, 6 May 2024 at 9 AM (EEST) Health Canada Approves Nexstim NBS 6 System for Treatment of MDD Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received approval from Health Canada for the [...]

Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca

06/05/2024 - 08:00

Completion of the additional equity investment of $140M by AstraZeneca, as previously announced on November 1 and 15, 2023 NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) a [...]

Cellectis annonce la réalisation de l’investissement additionnel d’AstraZeneca

06/05/2024 - 08:00

Réalisation de l’investissement additionnel de 140 millions de dollars d’AstraZeneca tel qu’annoncé le 1 er et le 15 novembre 2023 NEW YORK, 06 mai 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: [...]

Declaration of shares and voting rights April 30, 2024 - VALNEVA SE

06/05/2024 - 07:30

VALNEVA Declaration of shares and voting rights April 30, 2024 __________________________________________________________________________________________ Company name: VALNEVA Registered office: 6 rue Alain Bombard, [...]

Déclaration d’actions et de droits de vote - 30 avril 2024 - Valneva SE

06/05/2024 - 07:30

VALNEVA Déclaration d’actions et de droits de vote 30 avril 2024 __________________________________________________________________________________________ Dénomination sociale : VALNEVA Adresse du siège social : 6 rue [...]

Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Personalized Medicine in Middle East and North Africa (MEA) Region

06/05/2024 - 07:00

PRESS RELEASE - 06/05/2024, 07:00 CEST Biocartis and Merck to Collaborate on Improving Patient Access to Personalized Medicine in Middle East and North Africa (MEA) Region Biocartis (Mechelen, Belgium) announced an [...]

TAR-210 results show 90 percent recurrence-free survival and 90 percent complete response in patients with high-risk and intermediate-risk non-muscle-invasive bladder cancer, respectively

05/05/2024 - 20:39

Updated results reinforce the potential of TAR-210 to transform treatment of non-muscle-invasive bladder cancer with fibroblast growth factor receptor (FGFR) alterations 1 BEERSE, BELGIUM, May 05, 2024 (GLOBE NEWSWIRE [...]

BetterLife Announces Intent to Complete Private Placement of Units

04/05/2024 - 00:00

VANCOUVER, British Columbia, May 03, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU ), an emerging biotech company focused on the development and [...]

Compass Pathways to announce first quarter financial results on May 8, 2024

03/05/2024 - 22:58

LONDON, May 03, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will [...]

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03/05/2024 - 22:45

BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03/05/2024 - 22:30

CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs [...]

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03/05/2024 - 22:30

NEW YORK and WALTHAM, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (“Dianthus”), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement [...]

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

03/05/2024 - 22:30

MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life [...]